

April 22, 2019



## **Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019**

HOUSTON, April 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it will host a conference call to discuss its significant discovery for lung cancer, FDA Fast Track Designation and recent corporate events. The call will be at 4:30 p.m. ET on Wednesday, April 24, 2019.



Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live webcast, which is available in the Investor Relations section of the Company's website at [www.moleculin.com](http://www.moleculin.com). The Company will field live questions from equity analysts in a Q&A segment of this call. Participants may submit questions in advance for the Company to address in the Q&A segment by sending them to [info@moleculin.com](mailto:info@moleculin.com). A webcast replay will be available in the Investors section of the Company's website at [www.moleculin.com](http://www.moleculin.com) for 90 days. A teleconference replay will be available at (877) 344-7529 or (412) 317-0088, confirmation code 10130980, through May 1, 2019.

### **About Moleculin Biotech, Inc.**

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and AML, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin Biotech is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit <https://www.moleculin.com>.

**Contacts**

Joe Dorame, Robert Blum or Joe Diaz

Lytham Partners, LLC

602-889-9700

[mbrx@lythampartners.com](mailto:mbrx@lythampartners.com)

📄 View original content to download multimedia <http://www.prnewswire.com/news-releases/moleculin-announces-conference-call-to-discuss-significant-discovery-for-lung-cancer-and-fda-activity-on-wednesday-april-24-2019-300835421.html>

SOURCE Moleculin Biotech, Inc.